Times Reporter of Africa
SEE OTHER BRANDS

Following the news from Africa

Times Reporter of Africa: Press Releases

Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Times Reporter of Africa.

Press releases published on April 30, 2025

UPDATE -- Burgundy Diamond Mines reports first quarter 2025 results

UPDATE -- Burgundy Diamond Mines reports first quarter 2025 results

CALGARY, Alberta, April 30, 2025 (GLOBE NEWSWIRE) -- Burgundy Diamond Mines Limited (ASX:BDM) (Burgundy or the Company) provided the filing of its financial and operating results for the first quarter (Q1-2025) ended March 31, 2025, to the Australian Stock …

Unibit Solutions Digital Marketing Announces Francois Muscat Named WSI’s Q1 Top Contributor

Unibit Solutions Digital Marketing Announces Francois Muscat Named WSI’s Q1 Top Contributor

George, South Africa, April 30, 2025 (GLOBE NEWSWIRE) -- Unibit Solutions Digital Marketing, a leading digital marketing production center, announces that Francois Muscat, a valued WSI franchisee and owner of Unibit Solutions Digital Marketing, has been …

Medicenna Presents Promising Preclinical Data from its First-in-Class Tumor Targeted and Conditionally Activated Anti-PD-1-IL-2 Bifunctional Superkine at the Annual 2025 AACR Meeting

Medicenna Presents Promising Preclinical Data from its First-in-Class Tumor Targeted and Conditionally Activated Anti-PD-1-IL-2 Bifunctional Superkine at the Annual 2025 AACR Meeting

MDNA113 is a novel IL-13Rα2 tumor-targeted and “masked” anti-PD-1-IL-2 Superkine (anti-PD1-IL-2SK), engineered to precisely deliver clinically validated anti-PD1 and IL-2SK to the tumor microenvironment (TME) IL-13Rα2 is overexpressed by some of the most “ …

Rakovina Therapeutics Inc. Announces 2024 Financial Results and Provides Corporate Update

Rakovina Therapeutics Inc. Announces 2024 Financial Results and Provides Corporate Update

VANCOUVER, British Columbia, April 30, 2025 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V: RKV) (FSE: 7JO), a biopharmaceutical company advancing next-generation cancer therapies through artificial intelligence (AI)-powered drug discovery announced …

Silo Pharma’s SP-26 Ketamine Implant Meets All Endpoints in Fibromyalgia Study

Silo Pharma’s SP-26 Ketamine Implant Meets All Endpoints in Fibromyalgia Study

— Successfully demonstrates strong tolerability, sustained drug release and safety SARASOTA, FL, April 30, 2025 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“Silo,” or the “Company”), a developmental stage biopharmaceutical company focused on …

Integral Metals Reports Preliminary Geomicrobial Results from Burntwood Project, Highlights Biological Pathfinder Potential for REE Exploration

Integral Metals Reports Preliminary Geomicrobial Results from Burntwood Project, Highlights Biological Pathfinder Potential for REE Exploration

CALGARY, Alberta, April 30, 2025 (GLOBE NEWSWIRE) -- Integral Metals Corp. (CSE: INTG | OTC: ITGLF | FSE: ZK9) (the “Company” or “Integral”) is pleased to announce preliminary results from its 2024 geomicrobial survey at the Burntwood Project in northern …

Context Therapeutics Presents Preclinical and Translational Data for CT-95, a Mesothelin Targeting T Cell Engager, at 2025 AACR Annual Meeting

Context Therapeutics Presents Preclinical and Translational Data for CT-95, a Mesothelin Targeting T Cell Engager, at 2025 AACR Annual Meeting

Preclinical data demonstrates unique binding location of CT-95 on mesothelin and avoidance of binding to shed mesothelin  Data supports ongoing Phase 1 clinical trial for CT-95   PHILADELPHIA, April 30, 2025 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“ …

Stallion Uranium Announces Completion of Ground Gravity Survey over Coyote Target

Stallion Uranium Announces Completion of Ground Gravity Survey over Coyote Target

VANCOUVER, British Columbia, April 30, 2025 (GLOBE NEWSWIRE) -- Stallion Uranium Corp. (the “Company” or “Stallion”) (TSX-V: STUD; OTCQB: STLNF; FSE: FE0) is pleased to announce the successful completion of a ground gravity survey over its Coyote Target, …

InflaRx to Report First Quarter 2025 Results on May 7, 2025

InflaRx to Report First Quarter 2025 Results on May 7, 2025

JENA, Germany, April 30, 2025 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced that it will report its first quarter 2025 financial …

BioCryst to Present at Upcoming Investor Conferences

BioCryst to Present at Upcoming Investor Conferences

RESEARCH TRIANGLE PARK, N.C., April 30, 2025 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company plans to present at the following conferences: Citizens Life Sciences Conference in New York on Thursday, May 8, …

Emerita Files NI 43-101 Technical Report for the IBW Project, Marking a 35% Increase in Total Indicated Resources and a 44% Increase in Total Inferred Resources

Emerita Files NI 43-101 Technical Report for the IBW Project, Marking a 35% Increase in Total Indicated Resources and a 44% Increase in Total Inferred Resources

TORONTO, April 30, 2025 (GLOBE NEWSWIRE) -- Emerita Resources Corp. (TSX – V: EMO; OTCQB: EMOTF; FSE: LLJA) (the “Company” or “Emerita”) reports that it has filed the independent NI 43-101 compliant technical report for its Iberian Belt West Project (“IBW” …

XORTX Provides Update on FDA Type B Meeting Request

XORTX Provides Update on FDA Type B Meeting Request

● XORTX will focus on key steps to advance a NDA filing for Gout indication ● CALGARY, Alberta, April 30, 2025 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late stage clinical …

Apellis Pharmaceuticals to Host Conference Call on May 7, 2025, to Discuss First Quarter 2025 Financial Results

Apellis Pharmaceuticals to Host Conference Call on May 7, 2025, to Discuss First Quarter 2025 Financial Results

WALTHAM, Mass., April 30, 2025 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced that the company will host a conference call and webcast to discuss its first quarter 2025 financial results on Wednesday, May 7, 2025, at 8:30 …

OKYO Pharma Announces Plans to Accelerate the Clinical Development of Urcosimod to Treat Neuropathic Corneal Pain

OKYO Pharma Announces Plans to Accelerate the Clinical Development of Urcosimod to Treat Neuropathic Corneal Pain

Urcosimod phase 2 trial treating Neuropathic Corneal Pain (“NCP”) patients was initiated in October 2024 and designed as a double-masked, randomized, 12-week placebo-controlled trial. OKYO Pharma plans to analyze the efficacy data from the 17 patients who …

PL BioScience Launches World’s Only Patented Gamma-irradiated Human Platelet Lysate

PL BioScience Launches World’s Only Patented Gamma-irradiated Human Platelet Lysate

New high-quality cell growth supplement for cell manufacturing applications including in regenerative medicine and cell therapies Human Platelet Lysate (HPL) offers a safer and sustainable alternative to Fetal Bovine/ Calf Serum (FBS/FCS) Gamma-irradiated …

BitMEX introduce la negociación gratuita de bitcoin al contado hasta que este alcance un valor de 100.000 dólares

BitMEX introduce la negociación gratuita de bitcoin al contado hasta que este alcance un valor de 100.000 dólares

VICTORIA, Seychelles, April 30, 2025 (GLOBE NEWSWIRE) -- BitMEX, la bolsa de criptoderivados más segura, anunció hoy que todos los usuarios activos en su plataforma pueden disfrutar de operaciones al contado con bitcoin sin comisiones realizadas desde …

Er-Kim Announces Exclusive Distribution Agreement with Puma Biotechnology to Commercialize NERLYNX® (neratinib) for Breast Cancer Patients

Er-Kim Announces Exclusive Distribution Agreement with Puma Biotechnology to Commercialize NERLYNX® (neratinib) for Breast Cancer Patients

ATHENS, Greece and LOS ANGELES, April 30, 2025 (GLOBE NEWSWIRE) -- Er-Kim, an international pharmaceutical company specializing in the commercialization of novel therapies in the EMEA region, today announced that it has signed an agreement with Puma …

Fortuna renews share repurchase program

Fortuna renews share repurchase program

VANCOUVER, British Columbia, April 30, 2025 (GLOBE NEWSWIRE) -- Fortuna Mining Corp. (NYSE: FSM | TSX: FVI) announced today that the Toronto Stock Exchange has approved the renewal of Fortuna’s normal course issuer bid (the “NCIB”) to purchase up to five …

Rakovina Strengthens Board with Appointments of Yevgeniy Meshcherekov and David Kideckel

Rakovina Strengthens Board with Appointments of Yevgeniy Meshcherekov and David Kideckel

VANCOUVER, British Columbia, April 29, 2025 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V: RKV) (FSE: 7JO), a biopharmaceutical company advancing innovative cancer therapies through artificial intelligence (AI)-powered drug discovery, is pleased to …

Appendix 4c Quarterly Activity Report for Quarter Ended March 31, 2025

Appendix 4c Quarterly Activity Report for Quarter Ended March 31, 2025

NEW YORK, April 29, 2025 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today provided highlights of its recent activities for the third quarter ended March 31, 2025. …

Share us

on your social networks:
AGPs

Get the latest news on this topic.

SIGN UP FOR FREE TODAY

No Thanks

By signing to this email alert, you
agree to our Terms of Service